Thromboresistance of balloon-injured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor

Circulation

Volumn 101, Issue 3, 2000, Pages 289-295

  Zoldhelyi, Pierre ^a,b   McNatt, Janice ^b   Shelat, Harnath S ^a,b   Yamamoto, Yasutaka ^a   Chen, Zhi Qiang ^a,b   Willerson, James T ^a,b  

^a TEXAS HEART INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Angioplasty; Cerebrovascular disorders; Coagulation; Genes; Thrombosis

Indexed keywords

ADRENALIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; CAROTID ARTERY FLOW; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; EXPRESSION VECTOR; GENE THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHEAR STRESS; SWINE; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME;

EID: 0034711777     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.3.289     Document Type: Article

References (30)

1. Rappaport SI, Rao LVM. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb. 1992;12:1111-1121.
2. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal blood vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA. 1989;86:2839-2843.
3. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernández-Ortiz A, Chesebro JH, Badimon L, Nemerson Y, Fuster V, Badimon JJ. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation. 1997;95:594-599.
4. Haskel EJ, Torr SR, Day KC, Haskel EJ, Torr SR, Day KC, Palmier MO, Wun TC, Sobel BE. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circulation. 1991;84:821-827.
5. Jang Y, Guzman LA, Lincoff M, Topol EJ. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation. 1995;92: 3041-3050.
6. Oltrona L, Speidel CM, Recchia D, Wickline SA, Eisenberg PR, Abendschein DR. Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs. Circulation. 1997;96:646-652.
7. Broze GJ Jr. TFPI and the revised theory of coagulation. Annu Rev Med. 1995;46:103-112.
8. Marmur J, Thiruvikraman S, Fyfe B, Guha A, Sharma S, Ambrose J, Falloon J, Nemerson Y, Taubman MB. Identification of active tissue factor in human coronary atheroma. Circulation. 1996;94:1226-1232.
9. Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that its consists of three tandem Kunitz-type inhibitory domains. J Biol Chem. 1988;263:6001-6004.
10. Gomez-Foix AM, Coats WS, Baque S, Alam T, Gerard RD, Newgard CB. Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen metabolism. J Biol Chem. 1992;267:25129-25134.
11. Zoldhelyi P, McNatt J, Xu XM, Meidell R, Loose-Mitchell D, Willerson JT, Wu KK. Prevention of arterial thrombosis by adenovirus-mediated transfer of cyclooxygenase gene. Circulation. 1996;93:10-17.
12. Rade JJ, Schulick AH, Virmani R, Dichek D. Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury. Nat Med. 1996;2:293-298.
13. Hansen J-B, Sandset PM, Huseby KR, Huseby NE, Nordøy A. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man. Thromb Haemost. 1996;76:703-709.
14. Beaty CH, Howard CF, Caruso V. Potentiation with epinephrine of macaque platelet aggregation by other agonists: implications for studies on human atherosclerosis. Thromb Res. 1986;41:441-458.
15. Foils JD, Gallagher K, Rowe GG. Blood flow velocity reductions in stenosed canine coronary arteries: vasospasm or platelet aggregation. Circulation. 1982;65:248-255.
16. Golino P, Buja LM, Ashton JH, Kulkarni P, Taylor A, Willerson JT. Effect of thromboxane and serotonin receptor antagonists on intracoronary platelet deposition in dogs with experimentally stenosed coronary arteries. Circulation. 1988;78:701-711.
17. Eichhorn EJ, Graybum PA, Willard JE, Anderson HV, Bedotto JB, Carry M, Kahn JK, Willerson JT. Spontaneous alterations in coronary blood flow velocity before and after coronary angioplasty in patients with severe angina. J Am Coll Cardiol. 1991;17:43-52.
18. Anderson HV, Kirkeeide RL, Krishnaswami A, Weigelt LA, Revana M, Weisman HF, Willerson JT. Cyclic flow variations after coronary angioplasty in humans: clinical and angiographic characteristics and elimination with 7E3 monoclonal antiplatelet antibody. J Am Coll Cardiol. 1994;23:1031-1037.
19. 2 synthase inhibition and receptor blockade are effective in preventing spontaneous and epinephrine-induced canine coronary cyclic flow variations. J Am Coll Cardiol. 1990;16:705-713.
20. Lam JY, Chesebro JH, Steele PM, Badimon L, Fuster V. Is vasospasm related to platelet deposition? Relationship in a porcine preparation of arterial injury in vivo. Circulation. 1987;75:243-248.
21. Lin M-C, Almus-Jacobs F, Chen H-H, Parry GCN, Mackman N, Shyy JY-J. Shear stress induction of tissue factor. J Clin Invest. 1997;99: 737-744.
22. Verstraete M, Zoldhelyi P, Willerson JT. Specific thrombin inhibitors. In: Verstraete M, Fuster V, Topol EJ, eds. Cardiovascular Thrombosis: Thrombocardiology. Baltimore, Md: Lippincott-Raven Publishers; 1998.
23. Orvim U, Barstad RM, Vlasuk GP, Sakariassen KS. Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/factor VIIa or collagen in an ex vivo model of shear-dependent human thrombogenesis. Arterioscler Thromb Vasc Biol 1995;15: 2188-2194.
24. Ragni M, Cirillo P, Pascucci I, Scognamiglio A, D'Andrea D, Eramo N, Ezekowitz MD, Pawashe AB, Chiariello M, Golino P. Monoclonal antibody against tissue factor shortens tissue plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis. Circulation. 1996;93:1913-1918.
25. Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, Frisco D, Pepe G, Abbate R, Gensini GF, Neri Serneri GG. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb Haemost. 1998;79:495-499.
26. Caplice NM, Mueske CS, Kleppe LS, Simari RS. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor pathway activity. Circulation. 1998;98:1051-1057.
27. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. 1994;90:1631-1637.
28. Lafont A, Durand E, Vilde F, Moreyra C, Drechsel S, Mirshahi SS, Mirshahi M, Guerot C, Lemarchand P. Thrombus generation after adenovirus-mediated gene transfer into atherosclerotic arteries. Hum Gene Ther. 1998;9:2795-800.
29. Newman KD, Dunn PF, Owens JW, Schulick AH, Virmani R, Sukhova G, Libby P, Dichek DA. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest. 1995;96:2955-2965.
30. Channon KM, Fulton GJ, Gray JL, Annex BH, Shetty GA, Blazing MA, Peters KG, Hagen PO, George SE. Efficient adenoviral gene transfer to early venous bypass grafts: comparison with native vessels. Cardiovasc Res. 1997;35:505-513.